Colorectal cancer (CRC is the second most common malignancy in the Hungary, Prognosis is best when the disease is detected early; however, nearly two-thirds of newly diagnosed cases of CRC have lymph node involvement or metastatic disease. For years, 5-fluorouracil (FU)-based regimens represented the only viable treatment option for patients with metastatic CRC However, in recent years several newer agents have been added to the treatment arsenal for this disease. These agents include oxaliplatin, irinotecan and newer monoclonal antibodies targeting the epidermal growth factor receptor (cetuximab and panitumumab) and VEGF (bevacizumab). This review aims to discuss current systemic and targeted therapies for metastatic colon cancer with a focus on strategy of patient management, indications, toxicity and efficacy.
|Translated title of the contribution||Targeted therapy of colorectal cancers|
|Number of pages||5|
|Publication status||Published - Dec 1 2009|
ASJC Scopus subject areas